Alternative Income





As of Nov 30, 2025

ARB Highlights

ARB declined by -0.1% in November, as arbitrage spreads widened slightly.

Last month, nineteen public M&A deals were announced in North America, totalling more than \$130 billion. While several deals made the Fund's watchlist, none have yet made their way into the portfolio, given the yields on these "investment grade" mergers have not yet met ARB's hurdle rate. In contrast, there were ten SPAC IPOs in November, and the Fund participated in six of these deals.

Currently, ARB is 156.4% long and -10.0% short (166.4% gross), with 66% allocated to SPAC arbitrage and 34% to traditional merger arbitrage (including 17% to strategic M&A and 17% to leveraged buyouts).

We are <u>pleased to announce</u> that the Accelerate Arbitrage Fund (TSX: ARB) has once again been awarded a #1 global hedge fund performance ranking in the Merger Arbitrage category, as featured in the latest Barclay Managed Funds Report.

Type Event-driven	Structure Alternative ETF	Date Started April 07, 2020	Management Fee 0.95%	ARB NAV \$28.15		
Investment Manager	Distribution	Exchange	Currency	Distribution Yield 3.7%		
Accelerate	\$0.26 per quarter	TSX	CAD			

Risk Rating Low


Performance Fee

None

	onth 1%		onths 3%		YTD 0.7%		1 Year 11.2%		3 Years 7.1%		5 Yea 7.1%	. •	Inception 9.5%
Monthly	Returns												
	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sept	Oct	Nov	Dec	YTD
2025	-0.1%	0.7%	0.5%	3.2%	1.9%	1.4%	0.3%	-0.4%	1.2%	1.6%	-0.1%		10.7%
2024	0.5%	0.9%	1.8%	-0.2%	0.1%	0.3%	0.7%	0.0%	0.4%	0.3%	0.4%	0.5%	5.8%
2023	0.6%	-0.2%	0.4%	0.0%	0.4%	0.8%	-0.1%	0.6%	0.7%	-0.6%	1.5%	-0.1%	4.0%
2022	-1.4%	0.0%	0.5%	-0.1%	-1.1%	-0.3%	0.1%	0.1%	-0.4%	0.7%	-0.4%	0.9%	-1.5%
2021	10.4%	1.5%	-4.8%	1.3%	-0.9%	0.5%	-0.8%	-1.2%	0.9%	1.3%	0.4%	-0.7%	7.4%
2020				3.9%	0.8%	3.2%	0.4%	1.4%	2.7%	-1.1%	6.4%	9.2%	29.9%

Investment Growth

Time Period: April 6, 2020 to Nov 30, 2025



DISCLAIMER: Past performance is not indicative of future results. Performance is net of all estimated trading fees and performance fees. Investing involves varying degrees of risk and there can be no assurance that the future performance of any investment strategy will be profitable. This does not constitute investment advice. For a full list of securities, please go to www.AccelerateShares.com.



Alternative Income



As of Nov 30, 2025

About the Fund

The Accelerate Arbitrage Fund (TSX: ARB) is a merger arbitrage investment strategy. The Fund aims to generate consistent, low-volatility returns by investing in listed equity, debt or derivative securities of target companies involved in mergers or corporate actions, while selling short certain listed equity, debt or derivative securities of acquirer companies involved in mergers or corporate actions, where applicable.

What is Merger Arbitrage?


Merger Arbitrage is an investment strategy that capitalizes on the spread between a company's current share price and the consideration paid for its acquisition in light of an announced merger transaction. The merger risk premium— or the spread between the acquisition price and the trading price of a stock—compensates the arbitrageur for the risk of the acquisition failing to close. The merger arbitrageur's goal is to "lock in" the spread earned upon deal closing and to profit from buying a takeover stock at a discount to its acquisition price.

Five steps are followed when selecting deals and executing trades in ARB:



Investment Objectives

- Outperform the S&P Merger Arbitrage Index
- · Provide an attractive distribution yield
- Generate consistent, low-volatility returns



Top 20 Long Positions	Weight
Electronic Arts Inc	4.8%
Air Lease Corp	4.5%
Kellanova (formerly Kellogg Co)	3.5%
InterRent Real Estate Investment Trust	3.5%
PROS Holdings Inc	3.5%
TXNM Energy Inc	3.5%
Hologic Inc	3.4%
NuVista Energy Ltd	3.0%
Keyera Corp Rights	3.0%
Hillenbrand Inc	2.9%
Avidity Biosciences Inc	2.9%
CyberArk Software Ltd	2.8%
Guardian Capital Group Ltd	2.7%
Sapiens International Corp NV	2.7%
CSLM Digital Asset Acquisition	2.5%
Centurion Acquisition Corp	2.3%
Drugs Made In America Acquisition II Corp	2.2%
GP-Act III Acquisition Corp	2.2%
Axiom Intelligence Acquisition Corp 1	2.1%
Legato Merger Corp III	2.1%

For a full list of securities, visit www.AccelerateShares.com

DISCLAIMER: Past performance is not indicative of future results. Performance is net of all estimated trading fees and performance fees. Investing involves varying degrees of risk and there can be no assurance that the future performance of any investment strategy will be profitable. This does not constitute investment advice. For a full list of securities, please go to www.AccelerateShares.com.

